Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood ...

Lorundrostat, an experimental drug, may help lower blood pressure in people with uncontrolled hypertension, researchers ...

Stage 1 hypertension: SBP 140-159 or DBP 90-99 Stage 2 hypertension: SBP ≥160 or DBP ≥100 For patients age 50 or older, elevated SBP is a stronger cardiovascular risk factor than elevated DBP.

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...

Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat ...

Discover how controlling hypertension serves as a powerful shield for kidney function and the steps you can take to protect these essential organs.

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

Idorsia Pharmaceuticals has claimed FDA approval for aprocitentan as a treatment for resistant hypertension, becoming the first drug in the endothelin receptor antagonist class for that indication.

Pulmonary arterial hypertension (PAH) can be a challenging complication to manage during pregnancy; women with PAH who are ...

potential best-in-class agent." It estimates the market for drugs for uncontrolled hypertension to be worth $6.1 billion by 2040 for hypertension. AstraZeneca's (AZN.L), opens new tab experimental ...